ESR1 and breast carcinoma: Moreover, Ni et al. proved that specific targeting of AR, Wnt, or HER2 signaling impairs androgen-stimulated tumor cell growth, suggesting potential therapeutic approaches for ER−/HER2+ breast cancers (Ni et al. 2011).